LeonardPJamesMDPhD
Oncology • Fresh Meadows, NYHematologic Oncology, Thoracic Cancer
Senior Director, Clinical Research, Pfizer Oncology
Dr. James is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
17660 Union Tpke
Ste 360
Fresh Meadows, NY 11366Phone+1 718-460-2300
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
University of ChicagoResidency, Internal Medicine, 2002 - 2005
University of Washington School of MedicineClass of 2002
Certifications & Licensure
NY State Medical License 2005 - 2026
IL State Medical License 2002 - 2005
Publications & Presentations
PubMed
- 388 citationsLorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.Alice T. Shaw, Enriqueta Felip, Todd M. Bauer, Benjamin Besse, Alejandro Navarro
The Lancet. Oncology. 2017-12-01 - 352 citationsResensitization to Crizotinib by the Lorlatinib Alk Resistance Mutation L1198F.Alice T. Shaw, Luc Friboulet, Ignaty Leshchiner, Justin F. Gainor, Bergqvist S
The New England Journal of Medicine. 2016-01-06 - 486 citationsLorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyBenjamin Solomon, Benjamin Besse, Todd M. Bauer, Enriqueta Felip, Ross A. Soo
The Lancet. Oncology. 2018-12-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
